Molecular Formula | C6H6BrN |
Molar Mass | 172.02 |
Density | 1.494±0.06 g/cm3(Predicted) |
Melting Point | 32-36°C |
Boling Point | 74 °C / 17mmHg |
Flash Point | 64.3°C |
Solubility | Chloroform (Slightly), Ethyl Acetate (Slightly) |
Vapor Presure | 1.09mmHg at 25°C |
Appearance | Bright yellow crystal |
Color | Off-White to Light Yellow Low-Melting |
BRN | 107324 |
pKa | 3.59±0.10(Predicted) |
Storage Condition | Inert atmosphere,Room Temperature |
Refractive Index | 1.553 |
MDL | MFCD00661170 |
Physical and Chemical Properties | Light yellow liquid |
Use | Used as a pharmaceutical Intermediate |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
WGK Germany | 3 |
HS Code | 29333990 |
Hazard Class | IRRITANT |
introduction | 5-bromo-2-methylpyridine is an important pharmaceutical intermediate, which has broad prospects and huge market potential in the production of cardiovascular and cerebrovascular drugs and respiratory drugs. |
application | 5-bromo-2-methylpyridine is a promising pharmaceutical intermediate, which has broad prospects and huge market potential in the production of cardiovascular and cerebrovascular drugs and respiratory drugs. |
preparation | the mixture of diethyl malonate (42mL,1.28mol) and sodium hydrogen (4.8g,0.2mol) is slowly heated to 90 ℃, stirred for 1h, then heated to 120 ℃, stirred for 30min, and then cooled to room temperature. 5-nitro -2-chloropyridine (2)(25g,0.16mol) toluene (200mL) solution is added dropwise, the reaction solution is heated to 110 ℃ for 1.5h, cooled to room temperature and stirred for 15h. The solvent was evaporated under reduced pressure, 6NHCl(200mL) was added, heated and refluxed for 4 hours, and then cooled to room temperature. Sodium carbonate was adjusted to alkaline, extracted with ethyl acetate (6 × 100mL), combined with organic phase, and dried with anhydrous sodium sulfate for 6h. After extraction, the filtrate was evaporated to dry the solvent to obtain crude 5-nitro-2-methylpyridine (3),20.4g,94%. |
use | as a pharmaceutical intermediate |